Corametix

What Corametix does

CoraMetix Pty Ltd is a privately held, pre-commercial medical device company headquartered in Osborne Park, Western Australia, developing a next-generation heart valve replacement for patients with advanced valvular heart disease, including aortic stenosis and rheumatic heart disease. The company was founded in 2023 by Dr Elena De-Juan-Pardo (Chief Technical Officer, a recognised leader in high-resolution 3D printing) and Dr Abdul Ihdayhid (Chief Medical Officer, an interventional and structural cardiologist), with strategic advisory from Assoc Prof Mo Dirani through the Heart Foundation's Entrepreneur in Residence program. The team of approximately 9-10 people combines clinical cardiology, materials science, and engineering disciplines.

CoraMetix's core product is a bio-inspired heart valve engineered from specialised polymers and manufactured using Melt Electrowriting (MEW), an advanced microscale 3D printing technology that enables precise control over fibre architecture to replicate the mechanical and functional properties of native valve tissue. The patented design targets physiological haemodynamic restoration, enhanced durability, and the elimination or reduction of lifelong anticoagulation requirements relative to existing mechanical and bioprosthetic valves. The manufacturing platform is being developed for automated, high-throughput production at clinical volumes, with all systems designed and built in-house in Western Australia.

The company's business model is anchored on one-time medical device sales following regulatory approval and clinical translation. Its go-to-market is enterprise field sales to hospitals and cardiac care centres, with staged clinical evaluation (first-in-human studies leading to broader trials) as the pathway to market. CoraMetix is pre-revenue and remains focused on design freeze, regulatory progression, manufacturing scale-up, and the build-out of commercial leadership ahead of market entry.

Name

Corametix

Legal name

CoraMetix Pty Ltd

Website

https://corametix.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro industry

PRIMARYHLAHAFAB

Structural Heart Valves (TAVR/SAVR) & Valve Repair

Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

SECONDARYHLAHAFAH

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

SECONDARYIMAAAEAL

Process Industries (Chemicals, Food, Pharma Equipment Components) (Production AM Parts)

Industrials, Manufacturing & Construction/3D Printing/Additive Manufacturing for Production Parts (Industrial End-Use)

Keywords

• Bio-inspired heart valves
• Melt electrowriting 3D printing
• Cardiovascular implant devices
• Polymer heart valve replacement
• Structural heart disease treatment

Headquarters

HQ city

Perth

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Pre-commercial stage company developing heart valve implants. Revenue will be generated through sale of medical devices following regulatory approval and commercialization. The company is working toward clinical readiness and market entry.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Corametix is developing a next-generation bio-inspired heart valve replacement engineered from specialized polymers and manufactured using Melt Electrowriting (MEW), an advanced microscale 3D printing technology. The patented valve design replicates native valve tissue microstructure to restore natural haemodynamic performance, offering enhanced durability without requiring lifelong anticoagulation. The product targets patients with advanced valvular heart disease, including aortic stenosis and rheumatic heart disease.

Product overview

CoraMetix offers a single core product: a bio-inspired heart valve platform engineered from specialized polymers and manufactured using advanced three-dimensional printing (Melt Electrowriting). The product is designed as a replacement for failing heart valves, targeting patients with advanced valvular heart disease including aortic stenosis and rheumatic heart disease. The valve is bioinspired to mimic the natural collagen microstructure of healthy heart valve tissue, aiming to restore physiological function while eliminating the need for lifelong anticoagulation required by mechanical valves.

Differentiator

Problem solved

Functional benefit

Products and services

• CoraMetix Bio-inspired Heart Valve A next-generation heart valve replacement engineered from specialized polymers using Melt Electrowriting (MEW), an advanced microscale 3D printing technology. The bioinspired design replicates native valve tissue microstructure to restore natural haemodynamic performance while providing enhanced durability without requiring lifelong anticoagulation. Targeted at patients with advanced valvular heart disease including aortic stenosis and rheumatic heart disease.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• University of Western Australia (UWA)coreStrategic or Co-development PartnerUWA is a key research partner, with team members including Co-Founder Dr Elena De-Juan-Pardo affiliated with the university. The company received the Vice-Chancellor's Award in Research Impact and Innovation from UWA, indicating strong collaborative ties in materials science and engineering research.
• Government of Western Australia / Department of Energy and Economic DiversificationcoreStrategic or Co-development PartnerThe company won the WA Innovators of the Year 2024 Wesfarmers Wellbeing Platinum Award, indicating a strong partnership with the Western Australian government's economic development initiatives supporting innovation in the medical technology sector.
• Heart FoundationcoreStrategic or Co-development PartnerHeart Foundation supports CoraMetix through their Entrepreneur in Residence program with Assoc Prof Mo Dirani serving as an advisor. The company is featured on Heart Foundation media platforms sharing patient stories about next-generation heart valve technology.
• MTPConnectminorStrategic or Co-development PartnerMTPConnect is the Australian Medical Research and Commercialisation Organisation supporting medtech and pharma innovation. CoraMetix appears in MTPConnect media content featuring Australian medtech innovations including their 3D-printed heart valve technology.
• Global Startup AwardsminorGTM or Marketing PartnerCoraMetix was recognized as a finalist/winner in the Global Startup Awards, gaining international visibility and credibility as a leading global startup in the health technology space.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Foldax: Develops polymer (biopolymer LifePolymer) heart valves aiming to avoid anticoagulation and tissue-valve degeneration, directly comparable to CoraMetix's synthetic-polymer valve thesis.
• Xeltis: Builds polymer/electrospun bioabsorbable cardiovascular implants including valves, sharing CoraMetix's advanced-polymer, fibre-architecture manufacturing approach to next-gen valves.

Emerging players

• PolyVascular: Early-stage developer of 3D-printed polymer heart valves (initially pediatric), closely mirroring CoraMetix's use of additive manufacturing for polymer valves.

Regional players

• Anteris Technologies: Australian structural-heart company developing the DurAVR biomimetic aortic valve; shares geography and the aim of a more durable, physiological valve, though tissue-based rather than polymer.
• Venus Medtech: China-based transcatheter heart valve developer serving primarily its home market; comparable offering in valve replacement but in a different geography.

Broad incumbents

• Edwards Lifesciences: Global leader in surgical and transcatheter heart valves (SAVR/TAVR); the dominant incumbent CoraMetix would compete against in aortic valve replacement.
• Medtronic: Major structural heart player with TAVR and surgical valve portfolios, an established incumbent in the same valve-replacement market CoraMetix targets.
• Abbott: Large cardiovascular device maker with structural heart and valve repair/replacement products overlapping CoraMetix's target indication.
• Boston Scientific: Broad structural heart portfolio including transcatheter valve technologies, competing in the same cardiovascular implant space.
• Corcym: Dedicated heart valve and cardiac surgery company (formerly LivaNova heart valves), a specialized incumbent in the surgical valve market CoraMetix aims to enter.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/corametix

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corametix